Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The collaboration will center on expanding access to Eastman’s Esmeri technology
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
Subscribe To Our Newsletter & Stay Updated